COPENHAGEN: Novo Nordisk A/S is open to upgrading its New York Stock Exchange presence from American depositary receipts to a direct share listing, Chief Executive Maziar Mike Doustdar told the Financial Times.
Novo Nordisk is considering changing its NYSE listing to raise the Danish drug maker’s profile in the United States.
“I clearly do see some advantages with that,” Doustdar told the newspaper when asked whether the company would consider replacing its existing ADR structure with a direct NYSE listing. However, it disclosed no formal decision or timetable.
Novo Nordisk currently lists its B shares on Nasdaq Copenhagen under the symbol NOVO B. Its American depositary receipts trade on the New York Stock Exchange under the ticker NVO, according to the company’s investor materials.
Read: Novo Nordisk CEO Lars Jørgensen to Step Down
The company has not announced changes to those listings. A direct U.S. share listing would therefore change the ADR structure currently used by American investors.
Read: Novo Nordisk Partners With OpenAI to Expand AI Use
Doustdar became Novo Nordisk’s president and chief executive in August 2025. The company held its 2026 Capital Markets Day in London on September 21, outlining plans to expand its drug pipeline and U.S. business over the coming years.
